\n
\n
\n Date
\n Event
\n Sentiment
\n Move
\n Catalyst
\n
\n
\n
\n
\n
\n Jan 28
\n
\n
\n Corporate update<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n +3.0%
\n
\n
\n
\n Outlined 2026 value drivers and reiterated CLD-401 IND timing and platform goals.
\n
\n
\n
\n
\n Nov 17
\n
\n
\n Investor webinar<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n +0.0%
\n
\n
\n
\n Announced investor webinar covering RedTail data, IND progress, and financial trends.
\n
\n
\n
\n
\n Nov 13
\n
\n
\n Earnings and update<\/a>
\n
\n
\n
\n Neutral
\n
\n
\n
\n +0.7%
\n
\n
\n
\n Reported Q3 2025 results, capital raises, and SITC preclinical RedTail data.
\n
\n
\n
\n
\n Nov 10
\n
\n
\n Clinical data update<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n -2.8%
\n
\n
\n
\n
\n
\n Presented new CLD-401 preclinical data and reiterated IND-enabling work and partnerships.
\n
\n
\n
\n
\n Nov 04
\n
\n
\n Investor event<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n -2.0%
\n
\n
\n
\n
\n
\n Announced SITC investor event focused on RedTail and CLD-401 IND-enabling studies.
\n
\n
\n
\n <\/p>\n
Pattern Detected<\/p>\n
Preclinical and corporate updates around the RedTail\/CLD-401 program have generally produced modest price moves, with some positive news met by negative reactions.<\/p>\n
Recent Company History<\/p>\n
Over the last few months, Calidi has repeatedly highlighted its RedTail platform and lead candidate CLD-401. Events on Nov 4-17, 2025 and the Jan 28, 2026 corporate update all emphasized systemic tumor targeting, IL-15 superagonist expression, and an intended IND by end of 2026. Price reactions to these updates ranged from modest gains to declines, suggesting that similar preclinical and investor-relations news has not consistently driven strong upside despite a clear strategic focus on RedTail.<\/p>\n
\n This announcement highlights further positioning of Calidi\u2019s RedTail platform, focusing on bispecific T-cell engagers in solid tumors and reinforcing plans to file an IND by end of 2026 for CLD-401. It extends a series of RedTail-centric updates from late 2025 and early 2026. Investors may monitor progress of IND-enabling studies, additional preclinical data at forums like AACR-IO, and any strategic partnerships that could support clinical development and funding needs.
\n <\/p>\n
\n
\n bispecific t-cell engagers (bites)
\n
\n medical
\n
\n
<\/p>\n
“its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform”<\/p>\n
Bispecific T\u2011cell engagers (BiTEs) are engineered proteins that act like a molecular matchmaker, simultaneously attaching to a specific marker on a diseased cell (often a cancer cell) and to an immune T cell so the immune cell can recognize and kill the target. They matter to investors because successful BiTE therapies can create significant, ongoing revenue and rapidly change a biotech company\u2019s valuation, while clinical trial setbacks or safety concerns can cause large, sudden downside moves.<\/p>\n
<\/p>\n
\n
\n virotherapy
\n
\n medical
\n
\n
<\/p>\n
“RedTail is Calidi\u2019s systemically delivered virotherapy platform designed to selectively target tumors”<\/p>\n
Virotherapy is a medical approach that uses live viruses, often modified, to target and destroy diseased cells or deliver therapeutic genes, most commonly in cancer treatment. For investors, virotherapy matters because results from clinical trials, regulatory approvals, manufacturing scale-up and safety profiles determine whether a therapy can become a viable product; think of it as a precision tool whose clinical success and production challenges drive potential market value and risk.<\/p>\n
<\/p>\n
\n
\n tumor microenvironment (tme)
\n
\n medical
\n
\n
<\/p>\n
“designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high\u2011level expression”<\/p>\n
The tumor microenvironment (TME) is the immediate surrounding area of a tumor, including nearby cells, blood vessels, and supporting tissues that interact with the cancer cells. It plays a crucial role in how a tumor grows and spreads, much like how the environment around a plant influences its health and development. For investors, understanding the TME is important because it affects the success of treatments and innovations in cancer therapies, impacting the potential value of related biotech companies.<\/p>\n
<\/p>\n
\n
\n investigational new drug (ind)
\n
\n regulatory
\n
\n
<\/p>\n
“anticipates submitting an Investigational New Drug (IND) application for CLD-401 by the end of 2026”<\/p>\n
An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing \u2014 like getting a permit to run real-world experiments \u2014 which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company’s value.<\/p>\n
<\/p>\n
AI-generated analysis. Not financial advice.<\/p>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n 02\/12\/2026 – 08:00 AM
\n
\n
<\/p>\n
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI<\/a>) (\u201cCalidi\u201d or the \u201cCompany\u201d), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it will present data on its novel approach to the use of BiTEs in solid tumors by utilizing its systemically delivered RedTail platform at the AACR Immuno-Oncology (AACR-IO) conference being held in Los Angeles, California, from February 18-21, 2026.<\/p>\n RedTail is Calidi\u2019s systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high\u2011level expression of therapeutic genetic payloads directly within the tumor. CLD\u2011401, the lead candidate derived from the RedTail platform, is engineered to express high levels of IL\u201115 superagonist, a known T-cell activator, in the TME.<\/p>\n BiTEs have shown exceptional efficacy in hematological malignancies but have failed to show efficacy in solid tumors where the TME inhibits T-cell activity. In immunocompetent models of metastatic disease, the RedTail platform has demonstrated that it can alter the TME and induce T-cell activation through its ability to convert tumors into local producers of IL-15 superagonist. Given the high capacity for genetic payloads with RedTail, it is possible to have simultaneous high levels of expression of multiple tumor\u2011localized payloads, such as an IL-15 superagonist, along with a tumor-specific BiTE.<\/p>\n \u201cRedTail is a major leap forward in the delivery of genetic medicine via an engineered virus,\u201d said Eric Poma, PhD, Chief Executive Officer of Calidi. \u201cIt is able to avoid immune clearance allowing for systemic delivery but can only replicate and express payload in tumor cells.\u201d<\/p>\n \u201cOur work with RedTail continues to highlight the flexibility of the platform to deliver complex biologics directly within the tumor microenvironment\u201d said Antonio F. Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations at Calidi. \u201cWe believe simultaneous tumor-localized expression of a T-cell activator and BiTE via RedTail can remodel the TME to enable for T-cell engagement precisely where it is needed.\u201d<\/p>\n Calidi is currently conducting IND-enabling studies with CLD-401, the first lead candidate from its RedTail platform. The company anticipates submitting an Investigational New Drug\u00a0(IND) application for CLD-401 by the end of 2026. The Company continues to expand the functionality of the RedTail platform is also actively pursuing strategic partnerships to accelerate clinical development and broaden the impact of its RedTail platform.<\/p>\n About Calidi\u00a0<\/p>\n
![\"\"](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/02\/1770909262_91_ti.gif\"\/)
![\"\"](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/02\/Calidi-Biotherapeutics-Inc.png\")